These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 24517736)

  • 21. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective study of highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients.
    Rajesh R; Vidyasagar S; Varma DM; Naik A; Hegde BM; Guddattu V; Kamath A
    Int J Risk Saf Med; 2013 Jan; 25(1):53-65. PubMed ID: 23442298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment outcome of HAART-treated patients in a resource-limited setting: the Belgrade Cohort Study.
    Jevtović D; Dragovic G; Salemović D; Ranin J; Kušić J; Marinković J; Djurković-Djaković O
    Biomed Pharmacother; 2014 Apr; 68(3):391-5. PubMed ID: 24486106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.
    Galli M; Ridolfo AL; Adorni F; Cappelletti A; Morelli P; Massetto B; Piazza M; Gianelli E; Vaccarezza M; Gervasoni C; Moroni M
    Antivir Ther; 2003 Aug; 8(4):347-54. PubMed ID: 14518704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
    Maggiolo F; Ripamonti D; Torti C; Arici C; Antinori A; Quiros-Roldan E; Minoli L; Sighinolfi L; Nasta P; Suter F;
    Antivir Ther; 2006; 11(7):923-9. PubMed ID: 17302255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.
    Napravnik S; Keys JR; Quinlivan EB; Wohl DA; Mikeal OV; Eron JJ
    AIDS; 2007 Apr; 21(7):825-34. PubMed ID: 17415037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.
    Mocroft A; Ledergerber B; Viard JP; Staszewski S; Murphy M; Chiesi A; Horban A; Hansen AB; Phillips AN; Lundgren JD;
    J Infect Dis; 2004 Dec; 190(11):1947-56. PubMed ID: 15529259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of short-term success of antiretroviral therapy in HIV infection.
    Oette M; Kroidl A; Göbels K; Stabbert A; Menge M; Sagir A; Kuschak D; O'hanley T; Bode JG; Häussinger D
    J Antimicrob Chemother; 2006 Jul; 58(1):147-53. PubMed ID: 16687458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus.
    del Giudice P; Mary-Krause M; Pradier C; Grabar S; Dellamonica P; Marty P; Gastaut JA; Costagliola D; Rosenthal E;
    J Infect Dis; 2002 Nov; 186(9):1366-70. PubMed ID: 12402211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of antiretroviral therapy on pregnancy outcome in HIV-1 positive women.
    Kowalska A; Niemiec T; El Midaoui A; Burkacka E
    Med Wieku Rozwoj; 2003; 7(4 Pt 1):459-68. PubMed ID: 15010556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
    Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
    Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can the "seek, test, treat, and retain" strategy be effective in France?
    Cuzin L; Allavena C; Pugliese P; Rey D; Hoen B; Poizot-Martin I; Cabie A; Yazdanpanah Y;
    J Acquir Immune Defic Syndr; 2013 Apr; 62(4):e119-21. PubMed ID: 23933718
    [No Abstract]   [Full Text] [Related]  

  • 34. External validation of the Dat'AIDS score: A risk score for predicting 5-year overall mortality in people living with HIV aged 60 years or older.
    Hentzien M; Frossard J; Kouyos R; Prendki V; Damas J; Hofmann E; Braun D; Schmid P; Bernasconi E; Ragozzino S; Efthimiou O; Delpierre C; Allavena C; Bani-Sadr F; Calmy A;
    HIV Med; 2024 Jan; 25(1):72-82. PubMed ID: 37619609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV: seek, test, treat, and retain.
    Normand J; Montaner J; Fang CT; Wu Z; Chen YM
    J Food Drug Anal; 2013 Dec; 21(4):S4-S6. PubMed ID: 25278735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The very first year of PBJ.
    Soares R
    Porto Biomed J; 2017; 2(5):135. PubMed ID: 32258605
    [No Abstract]   [Full Text] [Related]  

  • 37. THE FIRST YEAR.
    Am J Public Health (N Y); 1924 Jul; 14(7):613-4. PubMed ID: 18011273
    [No Abstract]   [Full Text] [Related]  

  • 38. Our first year.
    Clin Mol Pathol; 1995 Dec; 48(6):M291. PubMed ID: 16696025
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparative Effectiveness of First Antiretroviral Regimens in Clinical Practice Using a Causal Approach.
    Cuzin L; Pugliese P; Allavena C; Katlama C; Cotte L; Cheret A; Cabié A; Rey D; Chirouze C; Bani-Sadr F; Flandre P;
    Medicine (Baltimore); 2015 Sep; 94(39):e1668. PubMed ID: 26426666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidences and risk factors of first-line HAART discontinuation: a limitation to the success of the "seek, test, treat, and retain" strategy?
    Keita M; Perbost I; Pugliese-Wehrlen S; Abel S; Pugliese P; Enel P; Cuzin L; Lang T; Delpierre C;
    AIDS Care; 2014; 26(8):1058-69. PubMed ID: 24517736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.